drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR NK cells)
drug_description
Allogeneic natural killer cells genetically engineered to express a chimeric antigen receptor targeting CD19; CAR engagement activates NK cytotoxic pathways to kill CD19-positive B-cell malignancies.
nci_thesaurus_concept_id
C170903
nci_thesaurus_definition
A preparation of natural killer (NK) cells engineered to express an inhibitory chimeric antigen receptor (iCAR) specific for the tumor-associated antigen (TAA) cluster of differentiation 19 (CD19), with potential immunostimulating and antineoplastic activities. Upon administration, anti-CD19 iCAR-NK cells recognize, bind to and induce selective cytotoxicity in CD19-expressing tumor cells. The iCAR is designed to spare normal cells from NK cell actions by including an inhibitory receptor that is activated upon binding to antigens that are present on normal cells only. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies.
drug_mesh_term
Natural Killer Cells
drug_category
CAR NK
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Allogeneic natural killer cells engineered to express an anti-CD19 chimeric antigen receptor bind CD19 on B cells, activating NK cytotoxic pathways (perforin/granzyme release and cytokine-mediated killing) to selectively lyse CD19-positive malignant cells; some designs include inhibitory signaling to reduce off-tumor effects.
drug_name
anti-CD19 CAR NK cells
nct_id_drug_ref
NCT05673447